Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The kinase polypharmacology landscape of clinical PARP inhibitors

17 Feb 2020

Abstract excerpt

Polypharmacology plays an important role in defining response and adverse effects of drugs. For some mechanisms, experimentally mapping polypharmacology is commonplace, although this is typically done within the same protein class. Four PARP inhibitors have been approved by the FDA as cancer therapeutics, yet a precise mechanistic rationale to guide clinicians on which to choose for a particular patient is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Integrated Circuits and Semiconductor Failure Analysis
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32066817
DOI: 10.1038/s41598-020-59074-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The kinase polypharmacology landscape of clinical PARP inhibitorsPMID 32066817Read ↗

Polypharmacology is an enduring and nearly universal property of kinase inhibitorsSemantic proximity Read ↗

Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)Semantic proximity Read ↗

PARP inhibitors: clinical development, emerging differences, and the current therapeutic issuesSemantic proximity Read ↗

Dual-Target Inhibitors Based on PARP1: New Trend in the Development of Anticancer ResearchSemantic proximity Read ↗

Spectrum and Degree of CDK Drug Interactions Predicts Clinical PerformanceSemantic proximity Read ↗

Targeted but Troubling: CYP450 Inhibition by Kinase and PARP Inhibitors and Its Clinical ImplicationsSemantic proximity Read ↗

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary TargetsSemantic proximity Read ↗

Integrated Single-Dose Kinome Profiling Data is Predictive of Cancer Cell Line Sensitivity to Kinase InhibitorsSemantic proximity Read ↗

Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World DataSemantic proximity Read ↗

Directing the use of DDR kinase inhibitors in cancer treatment.Semantic proximity Read ↗

Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVIDSemantic proximity Read ↗

Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical ActivitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.